64 related articles for article (PubMed ID: 22973946)
1. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
Yim JH; Kim EY; Bae Kim W; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Yoon JH; Shong YK
Thyroid; 2013 Jan; 23(1):58-63. PubMed ID: 22973946
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
[TBL] [Abstract][Full Text] [Related]
3. Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.
Sezer H; Yazıcı D; Terzioğlu T; Tezelman S; Canbaz HB; Yerlikaya A; Demirkol MO; Kapran Y; Çolakoğlu B; Çilingiroğlu EN; Alagöl F
Am Surg; 2023 Dec; 89(12):5996-6004. PubMed ID: 37309609
[TBL] [Abstract][Full Text] [Related]
4. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
5. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.
Slonimsky E; Tulchinsky M
Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402
[TBL] [Abstract][Full Text] [Related]
6. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
[TBL] [Abstract][Full Text] [Related]
7. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Siraj N; Al-Rasheed M; Al-Haqawi W; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2023; 14():1228049. PubMed ID: 37867506
[TBL] [Abstract][Full Text] [Related]
8. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.
Garcia Alves-Junior PA; de Andrade Barreto MC; de Andrade FA; Bulzico DA; Corbo R; Vaisman F
Endocrine; 2024 Feb; ():. PubMed ID: 38296913
[TBL] [Abstract][Full Text] [Related]
9. Stimulating thyroglobulin to TSH ratio predict long-term efficacy of
Yin X; Lu C; Sun D; Ji Y; Wang Y; Zheng H; Ma Z; Jia Q; Tan J; Zheng W
Endocrine; 2024 Jan; ():. PubMed ID: 38172344
[TBL] [Abstract][Full Text] [Related]
10. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract][Full Text] [Related]
11. Male Sex Is Not a Risk Factor for Prognosis in Postoperative Thyroid Cancer Patients: A Propensity Score Matching Study.
Zhou Y; Wang Y; Zhang Z; Yin X; Liu J; Zheng W
J Clin Endocrinol Metab; 2023 Nov; 108(12):3330-3337. PubMed ID: 37267432
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Changes of Urinary Exosomal Peptide Levels After Thyroidectomy in Patients with Thyroid Cancer: A
Wang CY; Shih SR; Chen KY; Chung YC; Huang PJ
Int J Nanomedicine; 2024; 19():4667-4677. PubMed ID: 38803995
[TBL] [Abstract][Full Text] [Related]
13. Thyroglobulin in differentiated thyroid cancer.
Evans C; Tennant S; Perros P
Clin Chim Acta; 2015 Apr; 444():310-7. PubMed ID: 25444737
[TBL] [Abstract][Full Text] [Related]
14. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score Analysis.
Piscopo L; Zampella E; Volpe F; Gaudieri V; Nappi C; Cutillo P; Volpicelli F; Falzarano M; Pace L; Cuocolo A; Klain M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627224
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4 cm papillary thyroid carcinoma.
Jang A; Jin M; Kim CA; Jeon MJ; Lee YM; Sung TY; Kim TY; Kim WB; Shong YK; Kim WG
Endocrine; 2023 Aug; 81(2):290-297. PubMed ID: 36913171
[TBL] [Abstract][Full Text] [Related]
17. Value of the Postablative Thyroglobulin Measurements for Assessment of Disease-Free Status in Patients with Differentiated Thyroid Cancer.
Dessoki N; Nasr I; Badawy A; Ali I
Indian J Nucl Med; 2019; 34(2):118-124. PubMed ID: 31040522
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend.
Malandrino P; Tumino D; Russo M; Marescalco S; Fulco RA; Frasca F
J Endocrinol Invest; 2019 Oct; 42(10):1223-1230. PubMed ID: 30963467
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial Treatment.
Klain M; Pace L; Zampella E; Mannarino T; Limone S; Mazziotti E; De Simini G; Cuocolo A
Front Endocrinol (Lausanne); 2019; 10():146. PubMed ID: 30930852
[No Abstract] [Full Text] [Related]
20. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
